Sign In
14 May 2014 09:20
14 May 2014
Rex Bionics plc
("Rex Bionics" or the "Company")
Director Dealing
Rex Bionics plc (AIM: RXB), the developer and manufacturer of REX products: hands-free robotic exoskeletons for use by wheelchair users, announces that it has received notification yesterday that Victoria Provis, a non-executive director of the Company, purchased 5,000 ordinary shares of £1.00 each ("Ordinary Shares") in the Company yesterday, at a price of 176.95 pence per share.
Following this purchase, Victoria Provis has an interest in 5,000 Ordinary Shares representing 0.03% of the entire issued share capital of the Company.
For further information please contact:
Rex Bionics Plc
Jeremy Curnock Cook, Chief Executive Officer
Peter Worrall, Chief Financial Officer
+44 (0)142 864 5416
Oriel Securities Limited (NOMAD and Broker)
Juliet Thompson/Jonathan Senior
+44 (0) 20 7710 7600
Consilium Strategic Communications
Mary-Jane Elliott / Emma Thompson / Jessica Hodgson / Lindsey Neville
rexbionics@consilium-comms.com
+44 (0) 203 709 5700
About Rex Bionics
Rex Bionics (AIM: RXB) is an AIM-listed developer and manufacturer of REX products, hands-free robotic exoskeletons for use by people with mobility impairments. Founded in Auckland, New Zealand by two robotics engineers with first-hand experience of wheelchair users and their needs, Rex Bionics focuses on producing products designed to enable wheelchair users to stand and walk autonomously without the need for crutches or supports and is the only company to mass produce hands-free walking devices for wheelchair users. Rex Bionics' marketed products: REX Rehab and REX Personal, can be used by people with complete spinal cord injury, but also by a much broader potential customer base, including people with multiple sclerosis and muscular dystrophy. In May 2014, Rex Bionics joined AIM with a fundraising of £10 million (gross) to scale up production, distribution and marketing internationally, in order to support growing demand for both REX products as well as developing the next generation of REX devices, REX 3.
For more information please visit, www.rexbionics.com
Follow the stocks
